Login / Signup

Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.

Andrzej BozekBarbara RogalaMartyna MiodonskaGiorgio Walter Canonica
Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2023)
The combination of HDM SCIT and omalizumab is significantly and progressively reducing ICS use and AX in a 24-month study. The combination is significantly more effective than the single treatments or placebo.
Keyphrases
  • multiple sclerosis
  • chronic obstructive pulmonary disease
  • allergic rhinitis
  • cystic fibrosis
  • double blind
  • phase iii